Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial
- 18 September 2013
- journal article
- Published by Elsevier in Clinical Oncology
- Vol. 26 (2) , 81-89
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialThe Lancet Oncology, 2011
- Mechanisms of Trastuzumab Resistance in Breast CancerAnti-Cancer Agents in Medicinal Chemistry, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational studyBMC Cancer, 2006
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Treatment of advanced breast cancerAnti-Cancer Drugs, 1996
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 1934